Miller Anestesia

280. Wittels B, Scott DT, Sinatra RS: Exogenous opioids

in human breast milk and acute neonatal neurobe-

havior: A preliminary study. Anesthesiology

73:864–869, 1990.

281. Spigset O: Anaesthetic agents and excretion in

breast milk. Acta Anaesthesiol Scand 38:94–103,

1994.

282. Doberczak TM, Kandall SR, Wilets I: Neonatal

opiate abstinence syndrome in term and preterm

infants. J Pediatr 118:933–937, 1991.

283. Edston E, van Hage-Hamsten M: Anaphylactoid

shock—a common cause of death in heroin addicts?

Allergy 52:950–954, 1997.

284. Alexander R, Hill R, LiphamWJ, et al: Remifentanil

prevents an increase in intraocular pressure after

succinylcholine and tracheal intubation. Br J

Anaesth 81:606–607, 1998.

285. Ng HP, Chen FG, Yeong SM, et al: Effect of remi-

fentanil compared with fentanyl on intraocular

pressure after succinylcholine and tracheal intuba-

tion. Br J Anaesth 85:785–787, 2000.

286. Stefano GB, Scharrer B, Smith EM, et al: Opioid and

opiate immunoregulatory processes. Crit Rev

Immunol 16:109–144, 1996.

287. Nelson CJ, Dykstra LA, Lysle DT: Comparison of

the time course of morphine’s analgesic and immu-

nologic effects. Anesth Analg 85:620–626, 1997.

288. Sacerdote P, Bianchi M, Gaspani L, et al: The effects

of tramadol and morphine on immune responses

and pain after surgery in cancer patients. Anesth

Analg 90:1411–1414, 2000.

289. Yeager MP, Procopio MA, DeLeo JA, et al: Intrave-

nous fentanyl increases natural killer cell cytotoxi-

city and circulating CD16(+) lymphocytes in

humans. Anesth Analg 94:94–99, 2002.

290. Murphy GS, Szokol JW, Marymont JH, et al: The

effects of morphine and fentanyl on the inflamma-

tory response to cardiopulmonary bypass in patients

undergoing elective coronary artery bypass graft

surgery. Anesth Analg 104:1334–1342, 2007.

291. Welters ID, Menzebach A, Goumon Y, et al: Mor-

phine inhibits NF-

B nuclear binding in human

neutrophils and monocytes by a nitric oxide–depen-

dent mechanism. Anesthesiology 92:1677–1684,

2000.

292. Singhal PC, Kapasi AA, Reddy K, et al: Morphine

promotes apoptosis in Jurkat cells. J Leukoc Biol

66:650–658, 1999.

293. Yin D, Mufson RA, Wang R, Shi Y: Fas-mediated

cell death promoted by opioids. Nature 397:218,

1999.

294. Ohara T, Itoh T, Takahashi M: Immunosuppression

by morphine-induced lymphocyte apoptosis: Is it a

real issue? Anesth Analg 101:1117–1122, 2005.

295. Egan TD: Intravenous drug delivery systems:

Toward an intravenous “vaporizer.”. J Clin Anesth

8:8s–14s, 1996.

296. van den Nieuwenhuyzen MC, Engbers FH, Burm

AG, et al: Target-controlled infusion of alfentanil for

postoperative analgesia: Contribution of plasma

protein binding to intra-patient and inter-patient

variability. Br J Anaesth 82:580–585, 1999.

297. Murdoch JA, Hyde RA, Kenny GN: Target-contro-

lled remifentanil in combination with propofol for

spontaneously breathing day-case patients. Anaes-

thesia 54:1028–1031, 1999.

298. Olkkola KT, Hamunen K, Maunuksela EL: Clinical

pharmacokinetics and pharmacodynamics of opioid

analgesics in infants and children. Clin Pharmaco-

kinet 28:385–404, 1995.

299. Minto CF, Schnider TW, Egan TD, et al: Influence

of age and gender on the pharmacokinetics and

pharmacodynamics of remifentanil. I. Model deve-

lopment. Anesthesiology 86:10–23, 1997.

300. Egan TD, Huizinga B, Gupta SK, et al: Remifentanil

pharmacokinetics in obese versus lean patients.

Anesthesiology 89:562–573, 1998.

301. Davies G, Kingswood C, Street M: Pharmacokine-

tics of opioids in renal dysfunction. Clin Pharmaco-

kinet 31:410–422, 1996.

302. Osborne R, Joel S, Grebenik K, et al: The pharma-

cokinetics of morphine and morphine glucuronides

in kidney failure. Clin Pharmacol Ther 54:158–167,

1993.

303. Murphy EJ: Acute pain management pharmacology

for the patient with concurrent renal or hepatic

disease. Anaesth Intensive Care 33:311–322,

2005.

304. Rudin A, Lundberg JF, Hammarlund-Udenaes M, et

al: Morphine metabolism after major liver surgery.

Anesth Analg 104:1409–1414, 2007.

305. Danziger LH, Martin SJ, Blum RA: Central nervous

system toxicity associated with meperidine use in

hepatic disease. Pharmacotherapy 14:235–238,

1994.

306. Tegeder I, Lotsch J, Geisslinger G: Pharmacokine-

tics of opioids in liver disease. Clin Pharmacokinet

37:17–40, 1999.

307. Scholz J, Steinfath M, Schulz M: Clinical pharmaco-

kinetics of alfentanil, fentanyl and sufentanil. An

update. Clin Pharmacokinet 31:275–292, 1996.

308. Baririan N, Van Obbergh L, Desager JP, et al: Alfen-

tanil-induced miosis as a surrogate measure of

alfentanil pharmacokinetics in patients with mild

and moderate liver cirrhosis. Clin Pharmacokinet

46:261–270, 2007.

309. Hudson RJ, Thomson IR, Burgess PM, Rosenbloom

M: Alfentanil pharmacokinetics in patients under-

going abdominal aortic surgery. Can J Anaesth

38:61–67, 1991.

310. Navapurkar VU, Archer S, Frazer NM, et al: Phar-

macokinetics of remifentanil during hepatic trans-

plantation. Anesthesiology 83:A382, 1995.

311. Gedney JA, Ghosh S: Pharmacokinetics of analge-

sics, sedatives and anaesthetic agents during cardio-

pulmonary bypass. Br J Anaesth 75:344–351, 1995.

312. Kentala E, Kaila T, Arola M, et al: Pharmacokinetics

and clinical response of hyoscine plus morphine

premedication in connection with cardiopulmo-

nary bypass surgery. Eur J Anaesthesiol 8:135–140,

1991.

313. Miller RS, Peterson GM, McLean S, Moller C: Effect

of cardiopulmonary bypass on the plasma concen-

trations of fentanyl and alcuronium. J Clin Pharm

Ther 22:197–205, 1997.

314. Hudson RJ, Thomson IR, Jassal R, et al: Cardiopul-

monary bypass has minimal effects on the pharma-

cokinetics of fentanyl in adults. Anesthesiology

99:847–854, 2003.

315. Hug CC Jr, Burm AG, de Lange S: Alfentanil phar-

macokinetics in cardiac surgical patients. Anesth

Analg 78:231–239, 1994.

316. Petros A, Dunne N, Mehta R, et al: The pharmaco-

kinetics of alfentanil after normothermic and hypo-

thermic cardiopulmonary bypass. Anesth Analg

81:458–464, 1995.

317. Hynynen M, Hynninen M, Soini H, et al: Plasma

concentration and protein binding of alfentanil

during high-dose infusion for cardiac surgery. Br J

Anaesth 72:571–576, 1994.

318. Russell D, Royston D, Rees PH, et al: Effect of tem-

perature and cardiopulmonary bypass on the phar-

macokinetics of remifentanil. Br J Anaesth

79:456–459, 1997.

319. Davis PJ, Wilson AS, Siewers RD, et al: The effects

of cardiopulmonary bypass on remifentanil kinetics

in children undergoing atrial septal defect repair.

Anesth Analg 89:904–908, 1999.

320. Michelsen LG, Holford NH, Lu W, et al: The phar-

macokinetics of remifentanil in patients undergoing

coronary artery bypass grafting with cardiopulmo-

nary bypass. Anesth Analg 93:1100–1105, 2001.

321. Egan TD, Kuramkote S, Gong G, et al: Fentanyl

pharmacokinetics in hemorrhagic shock: A porcine

model. Anesthesiology 91:156–166, 1999.

322. Johnson KB, Kern SE, Hamber EA, et al: Influence

of hemorrhagic shock on remifentanil: A pharma-

cokinetic and pharmacodynamic analysis. Anesthe-

siology 94:322–332, 2001.

323. Benrath J, Brechtel C, Martin E, Sandkuhler J: Low

doses of fentanyl block central sensitization in the rat

spinal cord in vivo. Anesthesiology 100:1545–1551,

2004.

324. Gottschalk A, Smith DS, Jobes DR, et al: Preemptive

epidural analgesia and recovery from radical pros-

tatectomy: A randomized controlled trial. JAMA

279:1076–1082, 1998.

325. Holthusen H, Backhaus P, Boeminghaus F, et al: Pre-

emptive analgesia: No relevant advantage of preope-

rative compared with postoperative intravenous

administration of morphine, ketamine, and cloni-

dine in patients undergoing transperitoneal tumor

nephrectomy. Reg Anesth Pain Med 27:249–253,

2002.

326. Aida S, Baba H, Yamakura T, et al: The effectiveness

of preemptive analgesia varies according to the type

of surgery: A randomized, double-blind study.

Anesth Analg 89:711–716, 1999.

327. Ong CK, Lirk P, Seymour RA, Jenkins BJ: The effi-

cacy of preemptive analgesia for acute postoperative

pain management: A meta-analysis. Anesth Analg

100:757–773, 2005.

328. Wasylak TJ, Abbott FV, English MJ, Jeans ME:

Reduction of postoperative morbidity following

patient-controlled morphine. Can J Anaesth

37:726–731, 1990.

329. Upton RN, Semple TJ, Macintyre PE: Pharmacoki-

netic optimisation of opioid treatment in acute pain

therapy. Clin Pharmacokinet 33:225–244, 1997.

330. Plummer JL, Owen H, Ilsley AH, Inglis S: Morphine

patient-controlled analgesia is superior to meperi-

dine patient-controlled analgesia for postoperative

pain. Anesth Analg 84:794–799, 1997.

331. Shapiro BA, Warren J, Egol AB, et al: Practice para-

meters for intravenous analgesia and sedation for

adult patients in the intensive care unit: An execu-

tive summary. Society of Critical Care Medicine.

Crit Care Med 23:1596–1600, 1995.

332. Dahaba AA, Grabner T, Rehak PH, et al: Remifenta-

nil versus morphine analgesia and sedation for

mechanically ventilated critically ill patients: A ran-

domized double blind study. Anesthesiology 101:

640–646, 2004.

333. Andrews DT, Leslie K, Sessler DI: Bjorksten AR: The

arterial blood propofol concentration preventing

movement in 50% of healthy women after skin inci-

sion. Anesth Analg 85:414–419, 1997.

334. Smith C, McEwan AI, Jhaveri R, et al: The interac-

tion of fentanyl on the Cp

of propofol for loss of

consciousness and skin incision. Anesthesiology

81:820–828, 1994.

335. Vuyk J, Engbers FH, Burm AG, et al: Pharmacody-

namic interaction between propofol and alfentanil

when given for induction of anesthesia.Anesthesio-

logy 84:288–299, 1996.

336. Kazama T, Ikeda K, Morita K: Reduction by fentanyl

of the Cp

values of propofol and hemodynamic

responses to various noxious stimuli. Anesthesio-

logy 87:213–227, 1997.

337. Katoh T, Uchiyama T, Ikeda K: Effect of fentanyl on

awakening concentration of sevoflurane. Br J

Anaesth 73:322–325, 1994.

586

Farmacología y anestesia